Darovasertib: Clinical Trials

5 trials of Darovasertib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 recruiting, 1 completed. 3 Phase 2, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Active not recruiting 2, Completed 1
Phase 33Recruiting 2, Active not recruiting 1

Follow Darovasertib: new trials by email Literature Review of Darovasertib trials Research Report on Darovasertib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Darovasertib, Crizotinib (Xalkori) - Uveal Melanoma
Phase 3RecruitingIDEAYA Biosciences4502026-09-042026-11-12
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Darovasertib, Primary Local Therapy - Uveal Melanoma
Phase 3RecruitingIDEAYA Biosciences5202026-01-252026-05-06
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
IDE196, Crizotinib, Pembrolizumab - Metastatic Uveal Melanoma
Phase 2 / Phase 3Active not recruitingIDEAYA Biosciences4202023-10-312026-02-17
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Darovasertib - Uveal Melanoma
Phase 2Active not recruitingIDEAYA Biosciences1602023-07-032026-03-16
Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma
Darovasertib - Ocular Melanoma
Phase 2CompletedSt Vincent's Hospital, Sydney152022-05-032026-04-23

Conditions studied

Uveal Melanoma (5)  ·  Melanoma (2)  ·  Plaque, Amyloid (1)

Sponsors

IDEAYA Biosciences (4)  ·  St Vincent's Hospital, Sydney (1)

Countries

Australia (5)  ·  Canada (4)  ·  United States (4)  ·  France (3)  ·  Germany (3)  ·  Israel (3)  ·  Italy (3)  ·  Netherlands (3)  ·  Switzerland (3)  ·  United Kingdom (3)  ·  Belgium (2)  ·  Poland (2)  ·  Spain (2)  ·  Austria (1)  ·  Czechia (1)

Top investigators

Anthony Joshua, FRACP, MBBS, PhD (1)  ·  Hetal Patel, MD, MSHS, CHCQM (1)  ·  Jasgit Sachdev, MD (1)